SCHEMBL25324787

SCHEMBL25324787

O=C(N1CC(c2ccc(S(=O)(=O)c3ccccc3)cc2)C1)N1CC2(CC(c3nnc(C4CC4)[nH]3)C2)C1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.36
▸ HPGD P15428 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ CYP2C9 P11712 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ SCD5 Q86SK9 1/20 0.35
▸ HRH3 Q9Y5N1 3/20 0.35
▸ MGLL Q99685 3/20 0.34
▸ HTR2B P41595 2/20 0.34
▸ USP30 Q70CQ3 1/20 0.34
▸ NAMPT P43490 2/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ CA12 O43570 1/20 0.32
▸ CA1 P00915 1/20 0.32
▸ CA2 P00918 1/20 0.32
▸ CA7 P43166 1/20 0.32
▸ CA9 Q16790 1/20 0.32
▸ CA14 Q9ULX7 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25325378 0.88 CA1 (0.37) CA12CA1CA2CA7CA9
SCHEMBL25919717 0.88 HTR2B (0.45) LMNAHPGDHRH3HTR2BUSP30
SCHEMBL25326558 0.85 NAMPT (0.35) LMNACYP2C9MGLLHTR2BNAMPT
SCHEMBL25324952 0.85 MGLL (0.42) LMNASCD5MGLLSMN1; SMN2
SCHEMBL25326500 0.82 GPR119 (0.37) SCD5MGLL
SCHEMBL25327456 0.82 BRS3 (0.38) SCD5MGLL
SCHEMBL25327308 0.81 HSD11B1 (0.38) CYP2C9CYP2C19SCD5MGLL
SCHEMBL25327992 0.80 MGLL (0.42) LMNASCD5MGLLSMN1; SMN2
SCHEMBL25325184 0.79 MGLL (0.34) SCD5MGLL
SCHEMBL25325609 0.79 MGLL (0.33) SCD5MGLLHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250099448-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2025-03-27 — — US claimed
EP-4469446-A1 NEW HETEROCYCLIC COMPOUNDS F. Hoffmann-La Roche AG (CH) 2024-12-04 — — EP claimed
WO-2023144160-A1 NEW HETEROCYCLIC COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2023-08-03 — — WO claimed
US-20250099448-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2025-03-27 — — US disclosed
EP-4469446-A1 NEW HETEROCYCLIC COMPOUNDS F. Hoffmann-La Roche AG (CH) 2024-12-04 — — EP disclosed
WO-2023144160-A1 NEW HETEROCYCLIC COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2023-08-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250099448-A1 HETEROCYCLIC COMPOUNDS OPRM1, CYP1A1, CYP3A4 LMNA 3406/4885HPGD 352/4885KDM4E 1137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback